Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 40,413 shares, a growth of 106.2% from the April 15th total of 19,602 shares. Based on an average daily volume of 43,030 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

Pulmatrix Trading Down 0.5%

NASDAQ PULM traded down $0.01 on Monday, hitting $1.24. 16,743 shares of the stock traded hands, compared to its average volume of 38,446. The stock has a 50-day moving average of $1.56 and a 200 day moving average of $2.71. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $9.37. The company has a market capitalization of $4.54 million, a P/E ratio of -1.01 and a beta of 1.94.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).